AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice. 2007; 13(Supple 1):3-68.
http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf

American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30:S4-41. http://care.diabetesjournals.org/cgi/content/full/30/suppl_1/S4

American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-32. http://care.diabetesjournals.org/cgi/content/full/26/3/917

Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981;20:87-93. http://www.springerlink.com/content/x733060827627881/fulltext.pdf (PDF file)

Chen K-W, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of type 2 DM. Diabetes Care. 1995;18:747-53. http://care.diabetesjournals.org/cgi/content/abstract/18/6/747 (abstract only)

Davidson MB. Starting insulin therapy in type 2 diabetes patients. Does it really matter how? Diabetes Care. 2005;28:494-5. http://care.diabetesjournals.org/cgi/content/full/28/2/494

Department of Health and Human Services. Centers for Disease Control and Prevention. National Diabetes Fact Sheet 2005. www.cdc.gov/diabetes/pubs/factsheet05.htm.

Fritsche A, Schweitzer MA, Haring H-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138:952-9. http://www.annals.org/cgi/reprint/138/12/952.pdf (PDF file)

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93. http://content.nejm.org (requires free registration)

Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of type 2 DM in Mexican-Americans. Diabetes. 1995;44:1386-91. http://diabetes.diabetesjournals.org/cgi/content/abstract/44/12/1386 (abstract only)

International Diabetes Federation. Diabetes Atlas, third edition, Brussels, Belgium, 2006.

Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-9. http://care.diabetesjournals.org/cgi/content/full/28/2/254

Klein BE, Klein R, Moss SE, et al. Parental history of diabetes in a population-based study. Diabetes Care. 1996;19:827-30. http://care.diabetesjournals.org/cgi/content/abstract/19/8/827 (abstract only)

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20. http://care.diabetesjournals.org/cgi/content/full/27/1/17

Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocaridal infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-5. http://www.bmj.com/cgi/content/full/314/7093/1512

Malmberg, K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61. http://eurheartj.oxfordjournals.org/cgi/content/full/26/7/650

Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125-34.
http://www.annals.org/cgi/reprint/145/2/125.pdf

Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422-7. http://care.diabetesjournals.org/cgi/content/full/24/8/1422

Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72. http://care.diabetesjournals.org/cgi/content/full/29/8/1963

Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-9.
http://care.diabetesjournals.org/cgi/content/full/28/11/2673

Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-5.
http://care.diabetesjournals.org/cgi/content/full/28/2/260

Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6.
http://care.diabetesjournals.org/cgi/content/full/26/11/3080

Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with hman NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-5.
http://care.diabetesjournals.org/cgi/content/full/28/4/950

Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.
http://jama.ama-assn.org/cgi/content/full/291/3/335

Skovlund SE, Peyrot M, on behalf of the DAWN International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18:136-42. http://spectrum.diabetesjournals.org/cgi/content/full/18/3/136

Standl E, Maxeiner S, Raptis S, et al. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care. 2005;28:419-20. http://care.diabetesjournals.org/cgi/content/full/28/2/419

State of Diabetes in America. American Association of Clinical Endocrinologists. www.stateofdiabetes.com.

Turner RC, Holman RR, Cull CA, et al. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998; 352:837-853.
http://www.thelancet.com

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
http://www.thelancet.com (requires free registration)

Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-6. http://care.diabetesjournals.org/cgi/content/full/25/2/330

Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-51. http://www.springerlink.com/content/b5561706132w2245/fulltext.html